On November 4th, a reporter learned from Baiyang Pharmaceuticals...It has been learned that the company signed a deepened cooperation agreement with CSL, a leading global blood products company, on the same day. According to the agreement, Baiyang Pharmaceutical will acquire Ambow, a human serum albumin product from CSL.Exclusive promotion, sales and distribution rights for MI® in specific markets in China.

It is understood that this collaboration represents a further strengthening of the partnership between the two parties, building upon their cooperation in the retail market in 2018. Public information shows that human serum albumin can be used for emergency treatment of hypovolemia, treatment of significant hypoalbuminemia, treatment of neonatal hyperbilirubinemia, and as an adjunct therapy for acute respiratory distress syndrome, cardiopulmonary bypass, and plasma exchange in special types of hemodialysis. It is a commonly used drug in clinical emergency and critical care.

According to data from Moshang Consulting, the Chinese market for human serum albumin therapeutics has exceeded 30 billion yuan, and has long been dominated by imported products. Cetbeline, which has been in the Chinese market for nearly 40 years, is one of the major suppliers, with its related products accounting for nearly 24% of the market. Driven by its large population and aging trend, the clinical demand for human serum albumin in the Chinese market remains strong. Frost & Sullivan predicts that the Chinese market for human serum albumin therapeutics is expected to grow to 57 billion yuan by 2030, with a projected compound annual growth rate of 6.0% between 2025 and 2030.

It is understood that Ambrosial® is designed and manufactured by Jet Behring specifically for the Chinese market. It can be stored at room temperature, away from light, at temperatures not exceeding 30°C, and is suitable for complex cold chain logistics.The lower dependence on [certain substances] helps improve drug accessibility and supply chain stability, while also facilitating drug stockpiling at all levels of medical institutions. Baiyang Pharmaceuticals possesses the Fuzheng Huayu series of anti-fibrotic products and has commercialization capabilities and a mature market network in the field of liver disease treatment. This collaboration will better provide valuable comprehensive treatment solutions for liver disease patients.

https://finance.eastmoney.com/a/202511053555256322.html